Chemistry Reference
In-Depth Information
. 3.. Tsigelny,.I..F.;.Sharikov,.Y.;.Miller,.M..A.;.Masliah,.E..Mechanism.of.alpha-synuclein.
oligomerization. and. membrane. interaction:.Theoretical. approach. to. unstructured. pro-
teins.studies..
Nanomedicine: Nanotechnol Biol Med
.2008,.
4
.(4),.350-357.
. 4.. Lundvig,.D.;.Lindersson,.E.;.Jensen,.P..H..Pathogenic.effects.of.alpha-synuclein.aggre-
gation..
Mol Brain Res
.2005,.
134
.(1),.3-17.
. 5.. Baba,.M.;.Nakajo,.S.;.Tu,.P..H.;.Tomita,.T.;.Nakaya,.K.;.Lee,.V..M..Y.;.Trojanowski,.J..Q..
et. al..Aggregation. of. alpha-synuclein. in. Lewy. bodies. of. sporadic. Parkinson's. disease.
and.dementia.with.lewy.bodies..
Am J Pathol
.1998,.
152
.(4),.879-884.
. 6.. Giasson,.B..I.;.Duda,.J..E.;.Quinn,.S..M.;.Zhang,.B.;.Trojanowski,.J..Q.;.Lee,.V..M..Y..
Neuronal. alpha-synucleinopathy. with. severe. movement. disorder. in. mice. expressing.
A53T.human.alpha-synuclein..
Neuron
.2002,.
34
.(4),.521-533.
. 7.. Tabner,.B..J.;.Turnbull,.S.;.El-Agnaf,.O..M..A.;.Allsop,.D..Formation.of.hydrogen.perox-
ide.and.hydroxyl.radicals.from.A.beta.and.alpha-synuclein.as.a.possible.mechanism.of.
cell.death.in.Alzheimer's.disease.and.Parkinson's.disease..
Free Radical Bio Med
.2002,.
32
.(11),.1076-1083.
. 8.. Jarvis,.L..M..The.amyloid.question..
Chem Eng News
.2010,.
88
.(14),.12-17.
. 9.. Dean,.R..A.;.DeMattos,.R.;.Gelfanova,.V.;.Hale,.J.;.Lachno,.R.;.Racke,.M.;.Talbot,.J..
et. al.. ELISA-based. measurement. of. plasma. total.A[beta]1-40. and.A[beta]1-42,. and.
CSF. total. and. free.A[beta]1-40. and.A[beta]1-42. in. the. presence. of. solanezumab,. a.
mid-domain. anti-A. beta. antibody..
Alzheimer's Dementia
. 2009,.
5
. (4,. Supplement. 1),.
P133-P133.
. 10.. DeMattos,.R..B.;.Racke,.M..M.;.Gelfanova,.V.;.Forster,.B.;.Knierman,.M..D.;.Bryan,.
M.. T.;. Hale,. J.. E.. et. al.. Identiication,. characterization,. and. comparison. of. amino-
terminally. truncated. A[beta]42. peptides. in. Alzheimer's. disease. brain. tissue. and. in.
plasma. from. Alzheimer's. patients. receiving. solanezumab. immunotherapy. treatment..
Alzheimer's Dementia
.2009,.
5
.(4,.Supplement.1),.P156-P157.
. 11.. Ashcroft,.A..E..Mass.spectrometry.and.the.amyloid.problem—How.far.can.we.go.in.the.
gas.phase?.
J. Am. Soc. Mass. Spectrom
..2010,.21,.1087-1096.
. 12.. Parkinson's.Disease.Foundation..http://www.pdf.org/
. 13.. Bennett,.M..C..The.role.of.alpha-synuclein.in.neurodegenerative.diseases..
Pharmacol
Therapeut
.2005,.
105
.(3),.311-331.
. 14.. Parkinson,.J..An.essay.on.the.shaking.palsy.(Reprinted)..
J Neuropsych Clin N
.2002,.
14
.
(2),.223-236.
. 15.. National.Family.Caregivers.Association..http://www.nfcacares.org/
. 16.. Kaur,. D.;. Andersen,. J.. Does. cellular. iron. dysregulation. play. a. causative. role. in.
Parkinson's.disease?.
Ageing Res Rev
.2004,.
3
.(3),.327-343.
. 17.. Bueler,. H.. Impaired. mitochondrial. dynamics. and. function. in. the. pathogenesis. of.
Parkinson's.disease..
Exp Neurol
.2009,.
218
.(2),.235-246.
. 18.. Fukae,. J.;. Mizuno,.Y.;. Hattori,. N.. Mitochondrial. dysfunction. in. Parkinson's. disease..
Mitochondrion
.2007,.
7
.(1-2),.58-62.
. 19.. Double,. K.. L.;. Ben-Shachar,. D.;.Youdim,. M.. B.;. Zecca,. L.;. Riederer,. P.;. Gerlach,. M..
Inluence. of. neuromelanin. on. oxidative. pathways. within. the. human. substantia. nigra..
Neurotoxicol Teratol
.2002,.
24
.(5),.621-628.
. 20.. Forloni,.G.;.Terreni,.L.;.Bertani,.I.;.Fogliarino,.S.;.Invernizzi,.R.;.Assini,.A.;.Ribizzi,.G..
et.al..Protein.misfolding.in.Alzheimer's.and.Parkinson's.disease:.Genetics.and.molecu-
lar.mechanisms..
Neurobiol Aging
.2002,.
23
.(5),.957-976.
. 21.. Hald,.A.;.Lotharius,.J..Oxidative.stress.and.inlammation.in.Parkinson's.disease:.Is.there.
a.causal.link?.
Exp Neurol
.2005,.
193
.(2),.279-290.
. 22.. Fedorow,. H.;. Tribl,. F.;. Halliday,. G.;. Gerlach,. M.;. Riederer,. P.;. Double,. K.. L..
Neuromelanin.in.human.dopamine.neurons:.Comparison.with.peripheral.melanins.and.
relevance.to.Parkinson's.disease..
Prog Neurobiol
.2005,.
75
.(2),.109-124.
Search WWH ::
Custom Search